<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of neuropsychiatric symptoms of dementia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of neuropsychiatric symptoms of dementia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of neuropsychiatric symptoms of dementia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel Press, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven T DeKosky, MD, FAAN, FACP, FANA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth E Schmader, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mario F Mendez, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neuropsychiatric symptoms in Alzheimer disease (AD) and other types of dementia are extremely common and often much more troubling than cognitive symptoms [<a href="#rid1">1</a>]. This topic will review the causes and treatment of behavioral disturbance and other neuropsychiatric symptoms related to dementia. These symptoms include agitation, aggression, delusions, hallucinations, paranoia, wandering, depression, apathy, disinhibition, and sleep disturbances  (<a class="graphic graphic_table graphicRef95072" href="/z/d/graphic/95072.html" rel="external">table 1</a>). One or more of these symptoms are observed in 60 to 90 percent of patients with dementia; the prevalence increases with disease severity [<a href="#rid2">2-6</a>]. The presence of neuropsychiatric symptoms leads to greater functional impairment in patients with dementia and cognitive impairment [<a href="#rid6">6,7</a>]. These behaviors often accelerate or lead to nursing home placement [<a href="#rid7">7-11</a>]. </p><p>Treatment of the cognitive features of dementia, the approach to safety and societal issues related to dementia, and the palliative care of patients with advanced dementia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5073.html" rel="external">"Treatment of Alzheimer disease"</a> and  <a class="medical medical_review" href="/z/d/html/14139.html" rel="external">"Frontotemporal dementia: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/5092.html" rel="external">"Prognosis and treatment of dementia with Lewy bodies"</a> and  <a class="medical medical_review" href="/z/d/html/5086.html" rel="external">"Treatment of vascular cognitive impairment and dementia"</a> and  <a class="medical medical_review" href="/z/d/html/5080.html" rel="external">"Management of the patient with dementia"</a> and  <a class="medical medical_review" href="/z/d/html/86250.html" rel="external">"Care of patients with advanced dementia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SYMPTOM ASSESSMENT</span><span class="headingEndMark"> — </span>Neuropsychiatric symptoms are common in dementia, but may be under-reported by patients and families [<a href="#rid12">12,13</a>]. Screening for agitation and other neuropsychiatric symptoms in patients with dementia should be done at regular follow-up visits [<a href="#rid13">13</a>]. We ask both caregivers and patients explicit questions regarding such symptoms, for example, "Does the patient have any behaviors that worry you?" and "Do you/the patient have hallucinations, see things, or hear voices that aren't there?" and "How do you/the patient sleep at night?" Clinicians should regularly inquire about aggression, delusions, hallucinations, paranoia, wandering, depression, apathy, and disinhibition. The presence of either delusions or hallucinations is associated with increased risk for cognitive and functional decline; hallucinations predict institutionalization and death [<a href="#rid10">10</a>].</p><p>Behavioral disturbances commonly peak in the late afternoon or evening, a phenomenon often referred to as "sundowning." Sundowning affects up to two-thirds of patients with dementia and is closely related to disturbed circadian rhythms [<a href="#rid11">11,14-17</a>]. Risk factors include poor light exposure and disturbed sleep [<a href="#rid18">18</a>]. Sleep disorders are common in dementia but may also be a manifestation of or contributor to neuropsychiatric symptoms. A sleep history should be regularly assessed. (See  <a class="medical medical_review" href="/z/d/html/97863.html" rel="external">"Sleep-wake disturbances and sleep disorders in patients with dementia", section on 'Clinical assessment'</a>.) </p><p>Delusions are common in patients with Alzheimer disease (AD), with a reported prevalence of 30 percent in patients with severe AD [<a href="#rid2">2</a>]. A long-term follow-up study suggests that these may be more pervasive; among 456 patients with mild to moderate AD followed for a mean of 4.5 years, 34 percent had delusions at baseline, but 70 percent had them during at least one evaluation [<a href="#rid10">10</a>]. Paranoid delusions in particular can be very distressing to the patient or caregivers. Common paranoid delusions include beliefs that the house has been invaded, that personal objects have been misplaced or stolen, that family members have been replaced by impostors (Capgras syndrome), or that spouses have been unfaithful. By contrast, some delusions or hallucinations may be fleeting or unobtrusive, which impacts how aggressively that are treated. </p><p>Hallucinations are less frequent than delusions, present in 7 percent at baseline and in 33 percent at some point over the course of follow-up in patients with severe AD [<a href="#rid2">2,10</a>]. The presence of visual hallucinations early in the course of a dementing illness suggests dementia with Lewy bodies (DLB) disease, a disorder with very specific management issues. (See  <a class="medical medical_review" href="/z/d/html/5088.html" rel="external">"Clinical features and diagnosis of dementia with Lewy bodies"</a> and  <a class="medical medical_review" href="/z/d/html/5092.html" rel="external">"Prognosis and treatment of dementia with Lewy bodies"</a>.) </p><p class="headingAnchor" id="H565612757"><span class="h1">AGITATION OR AGGRESSION</span></p><p class="headingAnchor" id="H270370739"><span class="h2">Evaluation for underlying cause</span><span class="headingEndMark"> — </span>Agitation and other behavioral abnormalities can arise from a variety of underlying causes in patients with dementia, and identifying the genesis of the abnormal behavior is critical to effective management. In many patients, behavioral changes herald a new infection or medication toxicity. In others, agitation is driven by pain, fear, confusion, or poor sleep. As with physical symptoms such as shortness of breath, no single approach or medication can be expected to treat the symptom of agitation without regard to the underlying cause. New or worsening symptoms should prompt assessment of safety and evaluation for an underlying cause  (<a class="graphic graphic_algorithm graphicRef115346" href="/z/d/graphic/115346.html" rel="external">algorithm 1</a>). </p><p class="headingAnchor" id="H3765160221"><span class="h3">Medication side effects</span><span class="headingEndMark"> — </span>Medication toxicity is a common precipitant of neurobehavioral disturbances in patients with dementia. Individuals with dementia have an increased risk of adverse cognitive and behavioral effects from a range of medications, both prescribed and over the counter.</p><p>In particular, clinicians should consider anticholinergic side effects of drugs used to treat sleep disturbance, bladder incontinence, or other illnesses  (<a class="graphic graphic_table graphicRef100289" href="/z/d/graphic/100289.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/3013.html" rel="external">"Drug prescribing for older adults", section on 'Anticholinergic activity'</a>.)</p><p>Benzodiazepines and other hypnotics/sedatives are other drugs that should generally be avoided in patients with dementia due to risk of adverse cognitive effects, among others. (See <a class="local">'Drugs to avoid'</a> below.)</p><p class="headingAnchor" id="H3468306913"><span class="h3">Pain assessment</span><span class="headingEndMark"> — </span>Pain may also precipitate neuropsychiatric symptoms. Older adults with mild to moderate dementia can report pain reliably [<a href="#rid19">19</a>]. Both interview and observation should be used to determine whether pain reporting represents pain-related suffering, pain perseveration, or a signal of some other type of distress. (See  <a class="medical medical_review" href="/z/d/html/16525.html" rel="external">"Treatment of chronic non-cancer pain in older adults", section on 'Considerations for patients with dementia'</a>.)</p><p>In patients with advanced dementia who are unable to verbally communicate about their pain, clinicians must rely on caregiver reports and observational scales. Behavioral domains that should be observed and assessed include [<a href="#rid20">20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Facial expressions</p><p class="bulletIndent1"><span class="glyph">●</span>Verbalizations/vocalizations</p><p class="bulletIndent1"><span class="glyph">●</span>Body movements</p><p class="bulletIndent1"><span class="glyph">●</span>Changes in interpersonal interactions</p><p class="bulletIndent1"><span class="glyph">●</span>Changes in activity patterns/routines</p><p class="bulletIndent1"><span class="glyph">●</span>Mental status changes</p><p></p><p>A variety of tools are available to assess pain in older adults with advanced dementia; one commonly used scale that incorporates scoring on five areas is the Pain Assessment in Advanced Dementia (PAINAD)  (<a class="graphic graphic_table graphicRef59509" href="/z/d/graphic/59509.html" rel="external">table 3</a>) [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H270370732"><span class="h3">Delirium</span><span class="headingEndMark"> — </span>Delirium is an acute confusional state characterized by impairments in attention and behavior developing over a short period of time and often fluctuating over the course of the day. The most common causes of delirium are medical illnesses, substance intoxication, and medication side effects.</p><p>A concomitant medical illness (particularly urinary tract infection or pneumonia) and other causes of delirium must be considered whenever new behavioral disturbances arise in patients with dementia, particularly in the setting of an acute worsening in cognition  (<a class="graphic graphic_table graphicRef59893" href="/z/d/graphic/59893.html" rel="external">table 4</a>) [<a href="#rid22">22,23</a>]. Most behavioral symptoms have precipitants.</p><p>These possibilities should be ruled out prior to initiation of any treatment. (See  <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">"Diagnosis of delirium and confusional states"</a> and  <a class="medical medical_review" href="/z/d/html/4823.html" rel="external">"Delirium and acute confusional states: Prevention, treatment, and prognosis"</a>.) </p><p class="headingAnchor" id="H604694265"><span class="h3">Depression</span><span class="headingEndMark"> — </span>Agitation or aggression may be the primary manifestation of depression in a patient too impaired to express distress in any other manner. A therapeutic trial with antidepressant medication may be the only reasonable diagnostic strategy in difficult cases. (See <a class="local">'Clinical features and diagnosis'</a> below.)</p><p class="headingAnchor" id="H1114178252"><span class="h3">Sleep disorders</span><span class="headingEndMark"> — </span>Sleep-wake disturbances are common in patients with dementia and can be caused by a variety of factors. When sleep disturbances are prominent, daytime agitation is unlikely to improve until sleep has been optimized. Sleep disturbances can be caused by a variety of factors, and evaluation is essential to appropriate treatment. This topic is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/97863.html" rel="external">"Sleep-wake disturbances and sleep disorders in patients with dementia"</a>.)</p><p class="headingAnchor" id="H3959659190"><span class="h3">Misperception or misunderstanding</span><span class="headingEndMark"> — </span>There is a hierarchy of causes of misunderstanding. </p><p>This can be as simple as poor vision or poor hearing; hearing loss is very common in older adults and may be a factor in paranoia through misunderstanding. There is evidence that hearing loss accelerates cognitive decline, and the two together may increase risk of agitation [<a href="#rid24">24</a>]. Poor hearing may allow auditory hallucinations to emerge. Tinnitus may be misinterpreted or transformed into hallucinations, even musical ones. Poor vision can also be a source of visual hallucinations. (See  <a class="medical medical_review" href="/z/d/html/3017.html" rel="external">"Geriatric health maintenance", section on 'Vision screening'</a> and  <a class="medical medical_review" href="/z/d/html/3017.html" rel="external">"Geriatric health maintenance", section on 'Hearing loss'</a> and  <a class="medical medical_review" href="/z/d/html/5255.html" rel="external">"Approach to the patient with visual hallucinations", section on 'Etiologies'</a>.)</p><p>Misunderstanding may also be due to cognitive, language, or memory deficits; behavioral management is usually sufficient after analysis of the antecedent behaviors, but awareness of family and caretakers about the nature of these deficits is essential to recognize the precipitating perceptual, language, or memory error. (See <a class="local">'Nonpharmacologic therapies'</a> below.)</p><p class="headingAnchor" id="H1067224992"><span class="h3">Delusions</span><span class="headingEndMark"> — </span>Delusions emerge in dementia for many reasons. They often have a suspicious nature. The misunderstanding of others' behaviors may precipitate fleeting or unthreatening notions but also more permanent and fixed ones. One example is imposter (Capgras) syndrome, in which the patient believes that someone they know or recognize has been replaced by an imposter. Phantom boarder syndrome is another delusion that is described in patients with dementia.</p><p>If delusions appear to trigger aggression, pharmacologic treatment may be helpful or necessary, but the underlying belief can be very resistant to medications. (See <a class="local">'Severe or refractory symptoms'</a> below.)</p><p class="headingAnchor" id="H1560970328"><span class="h2">Initial management strategies</span><span class="headingEndMark"> — </span>A number of treatment options exist for the management of agitation in dementia  (<a class="graphic graphic_algorithm graphicRef115346" href="/z/d/graphic/115346.html" rel="external">algorithm 1</a>). A proactive approach, with early recognition and treatment of mild symptoms along with education and collaboration among health care providers, patients, caregivers, and community agencies on person-centered nonpharmacologic approaches, may provide maximal benefits and help to curb excessive use of antipsychotic drugs [<a href="#rid25">25-29</a>].</p><p>As discussed above, agitation and other behavioral abnormalities can arise from a variety of underlying causes in patients with dementia, and identifying the genesis of the abnormal behavior is critical to effective management. (See <a class="local">'Evaluation for underlying cause'</a> above.)</p><p class="headingAnchor" id="H456835347"><span class="h3">Assess risk of harm and ensure safety</span><span class="headingEndMark"> — </span>Patients with agitation may pose safety risks to themselves or others. When severe, agitation may require an elevated level of care, either temporarily or indefinitely. Safety strategies may include a higher level of practical support for family and other caregivers, increased one-on-one supervision, inpatient hospitalization, and, if risk or distress is severe, short-term pharmacotherapy. (See <a class="local">'Severe or refractory symptoms'</a> below.)</p><p>Assessing the associated caregiver distress is also important in determining the urgency of intervention. In some cases, aggression may manifest as abusive behavior toward the caregiver. Distressed or overburdened caregivers may benefit from increased supportive services, education, and community resources. (See <a class="local">'Support for caregivers'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h3">Nonpharmacologic therapies</span><span class="headingEndMark"> — </span>Caregivers should be counseled in strategies involving distraction and redirection, structured routines, and providing calm, reassuring responses when patients seem anxious  (<a class="graphic graphic_table graphicRef98510" href="/z/d/graphic/98510.html" rel="external">table 5</a>) [<a href="#rid13">13</a>]. Increasing evidence suggests that these approaches as well as a variety of other nonpharmacologic measures can be effective in reducing agitation and anxiety in patients with dementia [<a href="#rid13">13,30-32</a>]. </p><p>Behavioral interventions employ different strategies and techniques. These include identifying any preceding events that generate agitation, determining whether unmet needs can be anticipated and alleviated, and avoiding environmental triggers such as a sudden change in surroundings  (<a class="graphic graphic_table graphicRef98510" href="/z/d/graphic/98510.html" rel="external">table 5</a>) [<a href="#rid30">30,32</a>]. Behavioral approaches to agitation may also address sleep-wake disturbances, including insomnia, by focusing on establishing and maintaining consistent sleep and wake times as well as incorporating more exposure to natural, bright light during the early part of the day. (See  <a class="medical medical_review" href="/z/d/html/97863.html" rel="external">"Sleep-wake disturbances and sleep disorders in patients with dementia", section on 'Insomnia and other sleep-wake disturbances'</a>.)</p><p>A 2014 systematic review of nonpharmacologic interventions for agitation in dementia included 33 randomized trials with at least 45 participants; effective interventions in one or more trials were the implementation of activities, music therapy, sensory interventions such as massage, and person-centered communication skills training for caregivers [<a href="#rid33">33</a>]. For the most part, positive trials demonstrated evidence of short-term but not long-term benefit, or did not include long-term follow-up results.</p><p>As one example, a randomized, controlled trial studied 73 residents of skilled nursing homes who had aggression or agitation with assisted bathing [<a href="#rid34">34</a>]. Treatment groups were a usual care control group (showering); "person-centered showering," an intervention focused on resident comfort and preferences; and "towel-bath," an in-bed bag bath method that kept the resident covered at all times and cleansed by using gentle massage. Both treatment groups showed significant declines in all measures of agitation, aggression, and discomfort compared with controls. The postulated mechanism underlying the effectiveness of the improved personal care involved a reduction in the insistent, task-focused, impersonal, and intrusive "usual care" methods that can provoke agitation and aggression [<a href="#rid34">34</a>].</p><p>Other nonpharmacologic therapies have demonstrated some benefit for neuropsychiatric symptoms of dementia in small studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Aromatherapy has been studied in several small randomized trials in patients with dementia and agitation, with mixed results [<a href="#rid35">35</a>]. Aromatherapy is safe and well tolerated. Lemon balm or lavender oil are most frequently used and can be delivered by either inhalation or skin application. The mechanism by which these agents may be effective is unclear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exercise training in combination with caregiver education may improve outcomes in patients with Alzheimer disease (AD). A randomized trial in 153 community-dwelling patients with AD found that compared with routine medical care, patients who were assigned to exercise (goal minimum of 30 minutes per day) and whose caregivers received training in managing behavioral problems had improved physical functioning and less depression [<a href="#rid36">36</a>]. We have found that regular physical activity can be very useful in managing behaviors in some patients with dementia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Music therapy and pet therapy also have some evidence of efficacy [<a href="#rid37">37-40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In preliminary studies, massage and touch therapy appear to be potentially beneficial in the immediate management of agitated behavior and in encouragement to eat [<a href="#rid41">41</a>].</p><p></p><p class="headingAnchor" id="H611865040"><span class="h3">Pain management</span><span class="headingEndMark"> — </span>Pain is an important source of behavioral disturbances in patients with dementia. As discussed above, the assessment of pain in patients with advanced dementia who are unable to verbally report pain can be challenging and relies heavily on caregiver report and observation. (See <a class="local">'Pain assessment'</a> above.) </p><p>Regardless of the stage of dementia, pain management and drug prescribing should be approached pragmatically (see  <a class="medical medical_review" href="/z/d/html/16525.html" rel="external">"Treatment of chronic non-cancer pain in older adults", section on 'Considerations for patients with dementia'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Prescribe a trial of scheduled analgesics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use a stepped-care approach to analgesic prescribing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Start low, go slowly, but use enough.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitor the patient carefully to balance risks and benefits of pain treatment versus persistent pain. Adequate pain control may be observed as improvements in behavior and function [<a href="#rid42">42</a>].</p><p></p><p>One randomized study evaluated a systematic approach to pain evaluation and pharmacologic management in 352 patients with behavioral disturbances and dementia [<a href="#rid43">43,44</a>]. The intervention was a stepwise protocol that followed recommendations of the American Geriatrics Society, consisting of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, low-dose <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> patch, and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> [<a href="#rid45">45</a>]. After eight weeks, those in the intervention group had reduced neuropsychiatric symptoms and lower agitation scores, although cognition and daily function were not affected, and agitation scores were similar at 12 weeks.</p><p class="headingAnchor" id="H1560970366"><span class="h3">Antidementia drugs</span><span class="headingEndMark"> — </span>While the evidence for efficacy in the treatment of neurobehavioral symptoms is not robust, cholinesterase inhibitors are well tolerated and may have additional benefit for cognition and function. Therefore, we suggest starting a cholinesterase inhibitor for patients with neuropsychiatric symptoms and mild to moderate dementia. (See  <a class="medical medical_review" href="/z/d/html/5072.html" rel="external">"Cholinesterase inhibitors in the treatment of dementia"</a>.)</p><p>A 2015 systematic review and meta-analysis that included 15 randomized placebo-controlled trials of cholinesterase inhibitors for neuropsychiatric symptoms of dementia generally found small but statistically significant efficacy, similar to results of previous analyses [<a href="#rid46">46,47</a>]. The small benefits seen were of questionable clinical significance, and most studies included patients with relatively mild neuropsychiatric symptoms.</p><p>Patients with dementia with Lewy bodies (DLB) may have a more beneficial response to cholinesterase inhibitors than patients with AD. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5092.html" rel="external">"Prognosis and treatment of dementia with Lewy bodies"</a>.)</p><p>The potential efficacy of <a class="drug drug_general" data-topicid="10131" href="/z/d/drug information/10131.html" rel="external">memantine</a> to ameliorate the behavioral effects in AD requires further study. Post hoc analyses of clinical trial results suggest that patients assigned to memantine treatment may have diminished agitation/aggression, irritability, and other behavioral disturbances [<a href="#rid48">48,49</a>]. However, systematic reviews have concluded that studies have not demonstrated a clinically significant effect of memantine for neuropsychiatric symptoms of dementia [<a href="#rid46">46,50,51</a>].</p><p class="headingAnchor" id="H611864373"><span class="h3">Antidepressant medication</span><span class="headingEndMark"> — </span>Despite mixed results in clinical trials, we have found selective serotonin reuptake inhibitors (SSRIs)  (<a class="graphic graphic_table graphicRef57207" href="/z/d/graphic/57207.html" rel="external">table 6</a>), in particular <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a> (10 to 20 mg daily), useful in the management of agitation and paranoia in patients with AD, as the symptoms are often driven by a mood disorder that is poorly verbalized. As an alternative, <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">trazodone</a> (starting dose 25 mg at bedtime) is well tolerated and is often used for sleep onset in patients with dementia. The use of SSRIs and other antidepressants for management of depression in patients with dementia is discussed below. (See <a class="local">'Depression'</a> below.)</p><p>The US Food and Drug Administration (FDA) recommends a maximum daily dose of 20 mg of <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a> for patients older than 60 years of age [<a href="#rid52">52</a>]. Citalopram should be avoided in patients at increased risk for arrhythmias (eg, congenital long QT syndrome, hypokalemia, hypomagnesemia, active heart disease) and discontinued in patients with persistent corrected QT measurements &gt;500 milliseconds. We sometimes overlap with an antipsychotic (eg, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>) in the first few weeks, as the efficacy of the SSRI may require that time frame to emerge.</p><p>As with other drugs, when antidepressant agents are administered to patients with dementia, there should be an ongoing assessment of benefits versus harms, and consideration for withdrawing the medications should be made periodically. However, in one randomized study of 128 patients with dementia who were treated with SSRIs for an indication other than depression, withdrawal of medication was associated with significantly worse depressive symptoms and a nonsignificant worsening of neuropsychiatric symptoms [<a href="#rid53">53</a>].</p><p>The evidence of efficacy for SSRIs is limited. Authors of systematic reviews of randomized controlled trials have concluded that antidepressant agents are well tolerated but have limited evidence for efficacy in the treatment of neuropsychiatric symptoms of dementia other than depression [<a href="#rid50">50,54</a>]. Of six studies that compared SSRIs (<a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">fluvoxamine</a>) with placebo, only two trials found a benefit for citalopram in the reduction of neuropsychiatric symptoms such as reduced agitation and caregiver distress [<a href="#rid55">55-60</a>]. There was no difference in the rates of trial withdrawals due to adverse events for SSRIs compared with placebo. However, in one study that used a higher than currently recommended dose of citalopram, QT prolongation and worse cognitive scores were noted in the citalopram-treated patients [<a href="#rid60">60</a>]. In randomized trials that have compared SSRIs (citalopram, sertraline, fluoxetine) with antipsychotic agents (<a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a>, <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">perphenazine</a>) there was no difference between treatment groups in regard to benefit on neuropsychiatric symptoms nor on adverse events, although other studies have suggested risks with antipsychotic agents in this population [<a href="#rid55">55,58,61,62</a>]. (See <a class="local">'Mortality risk'</a> below.)</p><p><a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">Trazodone</a> was compared with placebo in one trial that found no benefit on neuropsychiatric symptoms [<a href="#rid63">63</a>]. Two trials that compared trazodone with <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> found no significant relative benefit or harm between these two treatments [<a href="#rid63">63,64</a>]. We sometimes trial trazodone in this setting, particularly in patients with sleep impairment, starting at 25 mg at bedtime and gradually increasing to effect or side effect, rarely in doses as high as 100 to 150 mg.</p><p>Some evidence suggests that deficits in the serotoninergic system have a major role in the production of behavioral symptoms in frontotemporal dementia (FTD). There is limited evidence of benefit, largely from uncontrolled observational studies, for serotonergic antidepressant agents in these patients. (See  <a class="medical medical_review" href="/z/d/html/14139.html" rel="external">"Frontotemporal dementia: Treatment", section on 'Serotonergic medications'</a>.)</p><p class="headingAnchor" id="H1560970380"><span class="h3">Drugs with uncertain benefit</span><span class="headingEndMark"> — </span>A number of antiseizure medications have been investigated for the treatment of neuropsychiatric symptoms in dementia because of their mood-stabilizing properties:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a> was effective in a placebo-controlled study of agitation in nursing home patients with advanced dementia [<a href="#rid65">65</a>]. Relatively low doses were used, with a modal dose of 300 mg/day achieving a mean serum level of 5.3 mcg/mL. However, a subsequent trial found no benefit [<a href="#rid66">66</a>], and a systematic review concluded that there is currently not enough evidence of benefit for carbamazepine to recommend its use for neuropsychiatric symptoms [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">Valproate</a> improved aggressive behavior in several earlier reports [<a href="#rid67">67,68</a>]. However, a systematic review that analyzed three randomized controlled trials and two studies of valproate concluded that neither the short- nor long-acting preparations were effective for treatment of neuropsychiatric symptoms of dementia [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> is often used because of its relatively mild side effect profile, but its efficacy is unproven, with one open-label prospective study showing little benefit [<a href="#rid69">69</a>]. For patients receiving this for postherpetic or neuropathic pain, we have found a modest benefit for agitation as collateral benefit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">Lamotrigine</a> has been advocated based on case reports, but no randomized, placebo-controlled studies have been published to date.</p><p></p><p>Other therapies with possible benefit include:</p><p class="bulletIndent1"><span class="glyph">●</span>Melatonin – The observation that circadian rhythm disturbances appear to be associated with depressed mood, impaired cognition, and behavioral and sleep disturbances has suggested a potential benefit for melatonin and/or light therapy in patients with dementia. Studies have had somewhat mixed results, but in the aggregate do not suggest convincing benefit for agitation [<a href="#rid70">70-76</a>]. Melatonin dose varied widely in published studies, ranging from 1.5 to 10 mg. Timing of administration was also variable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Light therapy – Increasing bright-light exposure in the mornings may have benefits independent of melatonin and can lead to improvement in sleep disturbances as well. (See  <a class="medical medical_review" href="/z/d/html/97863.html" rel="external">"Sleep-wake disturbances and sleep disorders in patients with dementia", section on 'Multicomponent behavioral therapy'</a>.)</p><p></p><p class="headingAnchor" id="H1560970387"><span class="h3">Drugs to avoid</span><span class="headingEndMark"> — </span>Benzodiazepines are not recommended for the management of neuropsychiatric symptoms of dementia. One randomized controlled trial of a benzodiazepine for neuropsychiatric symptoms of dementia found benefit for either intramuscular <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> or intramuscular <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> compared with placebo assessed two hours after treatment; the benefit of lorazepam was not sustained at 24 hours on one outcome scale [<a href="#rid77">77</a>].</p><p>Benzodiazepine side effects include worsening gait, potential paradoxic agitation, and possible physical dependence. Benzodiazepine use should be limited to brief stressful episodes, such as a change in residence or an anxiety-provoking medical event [<a href="#rid78">78</a>]. When used in this fashion, those with shorter half-lives should be preferred.</p><p>Antihistamines and other sedatives are discouraged because of high rates of side effects, particularly for drugs with anticholinergic effects, such as <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>. (See <a class="local">'Sleep disorders'</a> below.)</p><p class="headingAnchor" id="H1560970394"><span class="h2">Severe or refractory symptoms</span><span class="headingEndMark"> — </span>As with mild symptoms, management of severe symptoms requires ongoing collaboration among health care providers, patients, and caregivers and regular re-evaluation of the balance of risks and benefits.</p><p>When nonpharmacologic interventions and the above pharmacologic approaches fail to manage neuropsychiatric symptoms effectively and they result in severe distress or safety issues, acute pharmacologic therapy with an antipsychotic drug may become necessary. Efficacy is seldom complete, however, and often comes with a cost of side effects, including increased mortality. Clinicians should use one drug at a time, start with a low dose, and titrate slowly, as treatment may help some problems but cause or exacerbate others. There should also be an ongoing assessment of benefits versus harms, and withdrawal of medications should be considered periodically. </p><p>As discussed above, no single approach or medication can be expected to treat the symptom of agitation without regard to the underlying cause. Identifying the genesis of the abnormal behavior is critical to effective management. A concomitant medical illness, uncontrolled pain, medication toxicity, and other causes of delirium should be considered and ruled out whenever new behavioral disturbances arise. (See <a class="local">'Evaluation for underlying cause'</a> above.)</p><p class="headingAnchor" id="H12"><span class="h3">Antipsychotic drugs</span><span class="headingEndMark"> — </span>Atypical neuroleptics have been the agents of choice for treating psychotic symptoms and agitation in patients with dementia. However, these drugs may increase mortality and are not approved for the treatment of behavioral disorders in patients with dementia by the FDA. They should not be used routinely to treat neuropsychiatric symptoms of dementia [<a href="#rid79">79,80</a>]. </p><p>Nonetheless, their benefits often still outweigh their risks in patients with dementia when treatment of psychotic symptoms including hallucinations, paranoia, and delusions is critical to patient and caregiver safety, wellbeing, and quality of life. In the absence of other effective agents, we continue to advocate cautious use for severe aggression or psychosis when nonpharmacologic strategies have failed and quality of life is not being adequately addressed by other means, after informing the patients and families of the potential risks, including increased mortality. (See <a class="local">'Mortality risk'</a> below.)</p><p class="headingAnchor" id="H1560970458"><span class="h4">Clinical use</span><span class="headingEndMark"> — </span>Given the risk of increased mortality associated with the use of atypical neuroleptics in older adults with dementia (see <a class="local">'Mortality risk'</a> below), we reserve their use for patients who have neuropsychiatric symptoms, particularly psychosis, that are severe, debilitating, or posing safety risks [<a href="#rid80">80</a>]. There is often no good alternative. Somnolence is also of concern with all of these agents, and may be dose limiting.</p><p>In the absence of clear differences in efficacy among various drugs, selection of a specific drug is primarily based on consideration of side effects and individual patient characteristics. (See <a class="local">'Efficacy'</a> below and <a class="local">'Side effects'</a> below.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiation of treatment</strong> – In general, we prefer one of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">Olanzapine</a> can be started at a dose of 2.5 mg daily and titrated up to a maximum of 5 mg twice a day. This drug appears to be at least modestly effective for treating the neuropsychiatric symptoms of dementia in patients with AD or vascular dementia as discussed below. The incidence of extrapyramidal symptoms is low at doses of 5 mg per day or less, but metabolic side effects (eg, weight gain, diabetes, and hypercholesterolemia) can be more severe than with some other agents.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">Quetiapine</a> is an alternative, starting at a dose of 25 mg at bedtime and titrating up to a maximum of 75 mg twice a day. There are few data regarding the effectiveness of quetiapine in this setting.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="107981" href="/z/d/drug information/107981.html" rel="external">Pimavanserin</a> is a newer alternative antipsychotic agent with some limited evidence of efficacy in this setting; it is typically started at 34 mg daily. A serotonin-receptor modulator 5HT2A inverse agonist and antagonist with no dopamine D2 affinity, it has also been studied for Parkinson disease-related psychosis. Adverse effects include QT prolongation. (See  <a class="medical medical_review" href="/z/d/html/4900.html" rel="external">"Management of nonmotor symptoms in Parkinson disease", section on 'Refractory psychotic symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ongoing treatment</strong> – Treatment should be maintained only if benefits are apparent, and discontinuation should be attempted at regular intervals, weighing the risk of relapse versus the risk of adverse effects from continued treatment [<a href="#rid81">81,82</a>]. The American Psychiatric Association recommends that an attempt to taper and withdraw antipsychotic therapy be made within four months of initiation in patients who have responded to therapy and who have no prior history of relapse with medication taper [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1">For some patients, discontinuation of antipsychotic agents may not be possible. One randomized study examined relapse risk in 180 patients with AD and psychosis or agitation who had initially responded to treatment with <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a> [<a href="#rid83">83</a>]. Discontinuation of risperidone was associated with an increased risk of relapse over 16 weeks of follow-up: 60 versus 33 percent in those assigned to early discontinuation and 48 versus 15 percent in those assigned to delayed discontinuation. Another randomized trial evaluated 193 patients with dementia-related psychosis who initially responded to treatment with <a class="drug drug_general" data-topicid="107981" href="/z/d/drug information/107981.html" rel="external">pimavanserin</a> [<a href="#rid84">84</a>]. Patients were randomly assigned to continued treatment with pimavanserin versus placebo. The trial was stopped early for benefit; relapses were less common in pimavanserin versus placebo-treated patients (13 versus 28 percent; hazard ratio [HR] 0.35, 95% CI 0.17-0.73).</p><p></p><p class="bulletIndent1">In another trial in which eight nursing homes were cluster randomized to antipsychotic review, a social intervention, and/or an exercise program, antipsychotic review reduced antipsychotic use by 50 percent but resulted in worsened neuropsychiatric symptoms among residents with dementia, an effect that was partially mitigated by concurrent social intervention [<a href="#rid85">85</a>]. Patients with severe baseline irritability/lability and severe auditory hallucinations may be at increased risk for relapse [<a href="#rid86">86</a>]. </p><p></p><p class="headingAnchor" id="H13"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Despite the fact that these medications are widely used and believed to be efficacious, they have not been extensively studied in randomized controlled clinical trials. The trials that exist are often short, 6 to 12 weeks, despite the fact that patients are often maintained on these agents for much longer. Trials also often suffer from methodologic limitations [<a href="#rid50">50</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Typical antipsychotics – A systemic review of typical antipsychotics included two meta-analyses of 12 trials plus two additional studies of <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a>, <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">thioridazine</a>, <a class="drug drug_general" data-topicid="9993" href="/z/d/drug information/9993.html" rel="external">thiothixene</a>, <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a>, <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">trifluoperazine</a>, and acetophenazine, and concluded that, in the aggregate, there was no clear evidence of benefit for these agents in patients with dementia [<a href="#rid50">50</a>]. A Cochrane review concluded that haloperidol may help control aggression but not other neuropsychiatric manifestations of dementia [<a href="#rid87">87</a>]. No trials compared agents with one another.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atypical antipsychotics – These agents include <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, and <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> and have been somewhat more extensively studied. Two independently conducted systematic reviews have concluded that these agents have, at most, modest efficacy [<a href="#rid50">50,88</a>]. Of seven trials studied, four found a statistically significant benefit for the primary endpoint with olanzapine or risperidone; there were no studies of clozapine or quetiapine for this indication at the time of this analysis. A subsequent meta-analysis that included three randomized trials of quetiapine found no evidence that it confers benefit [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="107981" href="/z/d/drug information/107981.html" rel="external">Pimavanserin</a> is a newer antipsychotic agent, a serotonin-receptor modulator 5HT2A inverse agonist and antagonist with no dopamine D2 affinity, which has been studied for Parkinson disease-related psychosis. A trial in 181 patients with dementia due to AD and/or vascular dementia suggested efficacy for pimavanserin at 6 weeks but not at 12 weeks [<a href="#rid90">90</a>]. In a subsequent study, 351 patients with dementia-related psychosis were treated with open-label pimavanserin (20 or 34 mg once daily); 217 had a clinical response that was sustained at 12 weeks [<a href="#rid84">84</a>]. This was followed by a randomized trial of drug continuation versus placebo; a higher relapse rate (13 versus 28 percent) in the placebo-treated patients as noted above provides further evidence of the efficacy of this agent.</p><p></p><p>There are limited studies regarding the comparative efficacy of these agents. A subsequent small randomized clinical trial that compared the cholinesterase inhibitor <a class="drug drug_general" data-topicid="9529" href="/z/d/drug information/9529.html" rel="external">rivastigmine</a> and the atypical antipsychotic agent <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> for agitation in nursing home patients with AD found no benefit for either treatment compared with placebo [<a href="#rid91">91</a>].</p><p>A multicenter, double-blind trial randomly assigned 421 patients with AD and either psychosis, aggression, or agitation to treatment with either <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, or placebo [<a href="#rid92">92</a>]. Median time to discontinuation of drug for any reason was similar in all four groups (5.3 to 8.1 weeks). However, more patients taking placebo discontinued medication for lack of efficacy compared with those on olanzapine or risperidone (70 versus 39 and 44 percent, respectively). For patients still taking the assigned treatment at 12 weeks, there were no differences among groups in the percentages of patients who improved on the Clinical Global Impression of Change (CGIC) scale (range 21 to 32 percent). One limitation of the study was the inclusion of patients with a broad array of behavioral symptoms. It seems likely that a subset of patients, perhaps those with hallucinations, would have shown more clear improvement. However, the general use of antipsychotic drugs for the treatment of agitation in patients with AD should be avoided, as the benefit is likely to be small and offset by adverse effects. (See <a class="local">'Side effects'</a> below.)</p><p class="headingAnchor" id="H14"><span class="h4">Side effects</span><span class="headingEndMark"> — </span>The choice of specific antipsychotic drug used to treat hallucinations is driven by drug side effects such as sedation or extrapyramidal disturbances  (<a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">table 7</a>). The older low-potency typical (conventional) neuroleptics (eg, <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a> and <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">thioridazine</a>) are highly sedating, and their anticholinergic activity can worsen memory and cognition. High-potency neuroleptics (eg, <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> and <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">fluphenazine</a>) are associated with an often unacceptably high incidence of extrapyramidal side effects. In a trial of haloperidol, for example, there was a high rate of extrapyramidal side effects and decline in cognitive function even at relatively low doses of 1 to 5 mg [<a href="#rid50">50,93</a>].</p><p>Intravenous <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> has been associated with clinically significant QT prolongation and requires additional precautions regarding its use, including monitoring of QT interval and serum potassium. (See  <a class="medical medical_review" href="/z/d/html/14773.html" rel="external">"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects", section on 'QT interval prolongation and sudden death'</a>.)</p><p>While the atypical neuroleptics are perceived to have a lower incidence of adverse effects, this may be true only with low doses. Systematic reviews and clinical trials find that adverse events with these agents in patients with dementia are common and dose related [<a href="#rid50">50,88,91,92</a>]. These include extrapyramidal symptoms, confusion, somnolence, falls, and fractures  (<a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">table 7</a>). In 2017, the FDA issued a formal warning about the risk of falls and fractures and recommended that a fall risk assessment be completed when initiating antipsychotic treatment and recurrently for patients continuing on long-term antipsychotics. These second-generation agents also have a risk of QT prolongation. (See  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Adverse effects'</a>.)</p><p>Patients who have DLB may be especially sensitive to antipsychotic medication and may experience idiosyncratic, life-threatening adverse reactions. When pharmacotherapy is necessary for treatment of behavioral symptoms related to DLB, very low doses of atypical neuroleptics (eg, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>) should be used. Clozapine use requires regular blood monitoring due to risk of agranulocytosis [<a href="#rid94">94</a>]. <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">Risperidone</a> and the typical antipsychotic agents should not be used in patients who have DLB. (See  <a class="medical medical_review" href="/z/d/html/14772.html" rel="external">"Schizophrenia in adults: Guidelines for prescribing clozapine", section on 'Monitoring'</a> and  <a class="medical medical_review" href="/z/d/html/5092.html" rel="external">"Prognosis and treatment of dementia with Lewy bodies"</a>.)</p><p class="headingAnchor" id="H15"><span class="h4">Mortality risk</span><span class="headingEndMark"> — </span>Accumulating data from both observational studies and pooled analyses of randomized trials indicate that antipsychotic medications are associated with an increased risk of stroke, myocardial infarction, and death when used to treat behavioral symptoms in older adults with dementia, in particular those with vascular disease. The mechanism for this effect has not been firmly established. The medications may lead to weight gain, hyperinsulinemia, and diabetes and thereby increase cardiovascular risk. Alternatively, there may be a component of "reverse causality," ie, vascular disease that disrupts frontal lobe white matter pathways may predispose both to behavioral symptoms requiring neuroleptic use and to cardiovascular events. </p><p>In 2005, the FDA issued a boxed warning that second-generation antipsychotics (eg, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a>, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, and <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>) were associated with increased mortality when used for the treatment of behavioral symptoms in older adult patients with dementia [<a href="#rid95">95,96</a>]. Their findings were confirmed in an independently conducted meta-analysis, as well as a subsequent randomized, placebo-controlled study [<a href="#rid97">97,98</a>]. The reported odds ratio for increased mortality in these analyses ranged from 1.54 to 1.7, with an absolute increased risk of death that ranged from 1 to 2 percent (3.5 to 4.5 versus 2.2 to 2.6 percent). Additional studies found that <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> and other first-generation antipsychotics were also associated with increased mortality [<a href="#rid99">99,100</a>], leading the FDA to extend the boxed warning to all antipsychotics in 2008.</p><p>The excess mortality risk appears to be higher for first-generation than second-generation drugs and varies among different second-generation drugs, being highest for <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> and <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a> and lowest for <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> [<a href="#rid99">99-106</a>]. Both short-term and long-term treatment is problematic [<a href="#rid107">107</a>], and higher doses are associated with increased risk [<a href="#rid102">102,105</a>]. Concurrent use of nonsteroidal antiinflammatory drugs may also increase risk [<a href="#rid108">108</a>].</p><p>The magnitude of the absolute mortality risk associated with antipsychotic drugs in this population may be higher than previously estimated, based on results of a large retrospective case-control study that included &gt;90,000 older adults with dementia [<a href="#rid105">105</a>]. Compared with no treatment, the absolute increase in mortality risk in the first 180 days of antipsychotic treatment was 3.8 percent for <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> (number needed to harm [NNH]: 26), 3.7 percent for <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a> (NNH: 27), 2.5 percent for <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (NNH: 40), and 2.0 percent for <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> (NNH: 50). As a group, the second-generation antipsychotics showed a dose-response effect, with 3.5 percent greater absolute risk of mortality in the high-dose subgroup compared with the low-dose subgroup.</p><p>These estimates are higher than the 1 percent absolute increased risk of death that was found in a 2005 meta-analysis of randomized placebo-controlled trials [<a href="#rid97">97</a>]. One potential explanation for the difference is that the trials in the meta-analysis were conducted over a relatively short treatment period (10 to 12 weeks) [<a href="#rid97">97</a>], whereas the retrospective study estimated risk of a six-month period [<a href="#rid105">105</a>]. It is also possible that methodologic limitations in the retrospective study led to an overestimation of risk, since it is difficult to fully adjust for factors related to the symptom or behavior that prompted prescription of an antipsychotic drug (which by themselves could be associated with increased mortality).</p><p>The evidence regarding increased stroke risk associated with the use of atypical antipsychotic drugs is conflicting. While several studies have reported such a link [<a href="#rid50">50,109-111</a>], others have not [<a href="#rid112">112-114</a>]. A large population-based cohort study of adults aged ≥65 years found a similar risk of ischemic stroke among users of atypical versus typical antipsychotics, even among a subgroup at high risk (those with atrial fibrillation or prior stroke) [<a href="#rid113">113</a>].</p><p class="headingAnchor" id="H1138692747"><span class="h3">Dextromethorphan-quinidine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">Dextromethorphan</a> and <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a> as a combination pill (<a class="drug drug_general" data-topicid="16087" href="/z/d/drug information/16087.html" rel="external">dextromethorphan-quinidine</a> 20 mg/10 mg) is approved in the United States and elsewhere for symptomatic treatment of pseudobulbar affect [<a href="#rid115">115,116</a>]. Limited evidence suggests that it may provide some benefit for severe agitation in patients with dementia. When cost is not prohibitive and other management strategies have failed, a trial of dextromethorphan-quinidine may be reasonable, at least in outpatients.</p><p>In a single trial, 220 patients with probable AD dementia and clinically significant agitation were randomly assigned to receive <a class="drug drug_general" data-topicid="16087" href="/z/d/drug information/16087.html" rel="external">dextromethorphan-quinidine</a> or placebo in two consecutive five-week stages [<a href="#rid117">117</a>]. The majority of subjects were outpatients (&gt;90 percent), and most were already taking one or more antidementia drugs, an antidepressant (50 to 60 percent), and an antipsychotic (17 to 23 percent). The primary endpoint was change from baseline on the Neuropsychiatric Inventory (NPI) agitation/aggression domain (scale range, 0 to 12). In stage 1, mean NPI scores improved in both arms: from 7.1 to 3.8 in the drug therapy group and from 7.0 to 5.3 in the placebo group (between-group difference -1.5, 95% CI -2.3 to -0.7). Effects were similar in stage 2. Most other secondary endpoints also favored drug therapy, with the exception of quality-of-life indicators. The most common treatment-emergent adverse effects were falls (9 versus 4 percent), diarrhea (6 versus 3 percent), and urinary tract infection (5 versus 4 percent).</p><p>Although statistically significant, the observed between-group difference of 1.5 points on the NPI agitation/aggression domain is of uncertain clinical significance. The authors of the study powered the trial to detect a mean difference of 2.5 points, which could be interpreted to mean that the threshold for meaningful benefit was not met. The change in total NPI score, which has been used more widely as an outcome measure, did not meet the suggested minimum for a clinically important difference [<a href="#rid118">118</a>]. </p><p>Although <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> is widely available over the counter in doses used in the study, the dose of <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a> in the combination pill (10 mg) is much lower than oral formulations of generic quinidine (200 mg). The high cost of <a class="drug drug_general" data-topicid="16087" href="/z/d/drug information/16087.html" rel="external">dextromethorphan-quinidine</a> as a combination pill and apparently modest benefits may limit its role until results can be replicated in other studies and more diverse patient populations.</p><p><a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">Dextromethorphan</a> is a low-affinity N-methyl-D-aspartate antagonist, but its mechanism of action for treating agitation is not known. Proposed mechanisms include nicotinic receptor antagonism, serotonin and norepinephrine reuptake inhibition, and possible analgesic effect [<a href="#rid118">118</a>].</p><p class="headingAnchor" id="H1646849896"><span class="h3">Use of physical restraints</span><span class="headingEndMark"> — </span>Physical restraints are rarely indicated in the care of patients with dementia and should be used only for patients who pose an imminent risk of physical harm to themselves or others [<a href="#rid119">119</a>], with frequent evaluation of continued need. Reasons for the use of physical restraints must be documented adequately. The use of restraints (both physical and pharmacologic) is associated with an increased risk of falls, incontinence, and pressure ulcerations [<a href="#rid120">120</a>]. Before resorting to restraints we refer patients to in-patient geriatric psychiatry programs.</p><p>The need for restraints can be decreased by environmental changes that decrease the risk of falls or wandering and by careful assessment and treatment of possible causes of agitation [<a href="#rid119">119</a>]. Small randomized trials have shown that educational interventions for nursing home staff can reduce rates of restraint use while maintaining resident safety [<a href="#rid121">121-124</a>].</p><p class="headingAnchor" id="H1560970861"><span class="h1">DEPRESSION</span></p><p class="headingAnchor" id="H367079604"><span class="h2">Clinical features and diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of depression in patients with impaired cognition, or at least symptoms of impaired cognition, is complicated:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with depression alone can produce symptoms and signs of cognitive impairment, particularly in older adults, a phenomenon sometimes called "pseudodementia" or "dementia syndrome of depression." (See  <a class="medical medical_review" href="/z/d/html/1719.html" rel="external">"Diagnosis and management of late-life unipolar depression"</a>.)</p><p></p><p class="bulletIndent1">However, older adults who become depressed are at increased risk of having comorbid dementia or of developing dementia in the future [<a href="#rid125">125</a>]. The risk of developing Alzheimer disease (AD) associated with premorbid depression may be higher in men than women, and it may be independent of vascular disease [<a href="#rid126">126</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with dementia may develop apathy, sleep impairment, and social withdrawal that suggest the presence of depression, but that are entirely due to cognitive deficits. (See <a class="local">'Apathy'</a> below and <a class="local">'Sleep disorders'</a> below.)</p><p></p><p class="bulletIndent1">However, patients with dementia may become depressed in reaction to slipping mental capacity or as a direct biologic consequence of the underlying neurologic disorder.</p><p></p><p>Further complicating the conundrum, patients with depression or dementia, let alone those with both, often cannot offer much illumination on their own mood or mental ability.</p><p>We have experienced particular difficulty in patients with vascular dementia (multiple lacunar infarctions), some of whom have relatively mild dementia, often not meeting formal diagnostic criteria, but also have considerable apathy while also reporting depression. </p><p>Clinical studies to resolve this diagnostic problem have had mixed results, perhaps because of the lack of reliable tools to measure the relative contributions of depression and dementia in individual patients [<a href="#rid125">125</a>]. The American Association for Geriatric Psychiatry has proposed diagnostic criteria for depression in patients with AD  (<a class="graphic graphic_table graphicRef58421" href="/z/d/graphic/58421.html" rel="external">table 8</a>) [<a href="#rid127">127</a>]. A therapeutic trial with antidepressant medication may be the only reasonable diagnostic strategy in difficult cases. </p><p class="headingAnchor" id="H367079544"><span class="h2">Management</span><span class="headingEndMark"> — </span>There are relatively few studies to guide selection of an antidepressant medication to treat depression in patients with dementia [<a href="#rid128">128,129</a>]. We strongly prefer selective serotonin reuptake inhibitors (SSRIs) because of the anticholinergic activity of tricyclic antidepressants, which are associated with adverse effects in these patients. </p><p>Psychotherapy may be a useful but frequently underutilized treatment option in patients with mild to moderate dementia [<a href="#rid130">130,131</a>]. Options are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1719.html" rel="external">"Diagnosis and management of late-life unipolar depression"</a>.) </p><p>Selection of a specific SSRI is generally based upon the side effect profile, drug interactions, and cost  (<a class="graphic graphic_table graphicRef57207" href="/z/d/graphic/57207.html" rel="external">table 6</a>). <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">Sertraline</a> (starting at a dose of 25 mg) and <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a> are commonly used in this setting. Citalopram may also improve psychotic and other behavioral symptoms and may be particularly helpful if depression is a likely contributor to the symptoms, or if depression cannot be eliminated as a contributing factor when no other cause is apparent [<a href="#rid55">55</a>] (see <a class="local">'Antidementia drugs'</a> above). The dose of citalopram should not exceed 20 mg daily in older adult patients [<a href="#rid52">52</a>]. <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">Fluoxetine</a> has a long half-life and more drug interactions than other SSRIs, making it less desirable in older adults. <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">Paroxetine</a> is the most anticholinergic of the SSRIs and therefore can also theoretically affect cognition. Detailed information on drug interactions can be found in the <a class="external" href="/drug-interactions">Lexicomp drug interaction</a> program within UpToDate.</p><p>Clinical trials of SSRIs for depression in patients with dementia have had somewhat mixed results. Two multicenter trials with <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a> demonstrated efficacy with reasonably mild side effects [<a href="#rid57">57,132</a>]. However, a study in 131 patients with AD and depression found no efficacy for <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> after 12 and 24 weeks of therapy [<a href="#rid133">133,134</a>]. Finally, a randomized study comparing sertraline with placebo in 218 patients found no differences in depression scores at 13 or 39 weeks [<a href="#rid135">135</a>]. A meta-analysis of five studies concluded there was insufficient evidence to support the use of SSRIs for the treatment of depression in patients with AD, but acknowledged that study design precluded a conclusion of absence of benefit [<a href="#rid136">136</a>]. In many trials, a high response rate occurs in the placebo group, which may point to the temporary nature of some of the neuropsychiatric symptoms.</p><p>The atypical antidepressants such as <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> may also be effective but have not been well studied in AD. In a randomized trial of 219 patients with depression and AD, <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> was no more effective than placebo after 13 or 39 weeks of therapy [<a href="#rid135">135</a>]. </p><p>Tricyclic antidepressants can cause worsening confusion, likely due to their anticholinergic properties, and are not as well tolerated as SSRIs. In one study, for example, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> and <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> were equally effective for treating depressive symptoms in patients with AD, but 58 percent of amitriptyline-treated patients dropped out compared with 22 percent of those treated with fluoxetine [<a href="#rid137">137</a>]. <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">Nortriptyline</a> may be better tolerated than amitriptyline because of fewer anticholinergic effects. (See  <a class="medical medical_review" href="/z/d/html/1719.html" rel="external">"Diagnosis and management of late-life unipolar depression"</a>.)</p><p class="headingAnchor" id="H1034625627"><span class="h1">APATHY</span><span class="headingEndMark"> — </span>Apathy is a common symptom of dementia that can occur with or without comorbid depression. Patients with dementia and apathy are more likely to have functional impairment in activities of daily living, independent of other factors such as age, cognitive function, and depression [<a href="#rid138">138-140</a>]. As discussed above, distinguishing apathy from depression can be difficult if not impossible in some cases. (See <a class="local">'Clinical features and diagnosis'</a> above.)</p><p>Management of apathy is challenging, and the symptom may emerge early in the disease course and persist over time. Nonpharmacologic strategies have not been well studied for this specific symptom. Because the cholinesterase inhibitors may have some positive effect on apathy, we typically approach the symptom in a stepwise fashion, starting with a cholinesterase inhibitor if the patient has not yet been exposed to one. (See  <a class="medical medical_review" href="/z/d/html/5072.html" rel="external">"Cholinesterase inhibitors in the treatment of dementia"</a>.)</p><p>If apathy persists despite treatment with a cholinesterase inhibitor and is distressing to the patient or caregiver, pharmacologic options include a therapeutic trial of an antidepressant and <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a>.</p><p><a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">Methylphenidate</a> has shown benefit as an adjunctive therapy to <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a> in older adults with major depression [<a href="#rid141">141</a>], and smaller studies also suggest that it may improve apathy as well as other outcomes in patients with dementia [<a href="#rid142">142-145</a>]. In the largest trial of methylphenidate in 77 men with mild Alzheimer disease (AD), methylphenidate improved apathy scores compared with placebo over a 12-week treatment period (9.9-point greater improvement on an 18-point scale) [<a href="#rid143">143</a>]. Measures of cognition, functional status, caregiver burden, and depression also improved more in the methylphenidate group. The mean final dose of methylphenidate was 10 mg twice daily. Treatment was well tolerated, and the number and type of adverse effects were similar between groups.</p><p>Because <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> has the potential to precipitate agitation or worsen nighttime sleep, we suggest use of low doses (eg, starting with 5 mg once daily in the morning, maximum dose 10 mg twice daily, last dose no later than lunchtime) with careful monitoring during titration.</p><p class="headingAnchor" id="H1560969444"><span class="h1">SLEEP DISORDERS</span><span class="headingEndMark"> — </span>Sleep disturbances are common in patients with Alzheimer disease (AD), affecting an estimated 25 to 35 percent of patients [<a href="#rid146">146</a>]. Causes are multifactorial, but can include contributions from depression and anxiety, a decrease in daytime physical activity, nocturia, as well as side effects of medications (eg, vivid dreaming with cholinesterase inhibitors). This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/97863.html" rel="external">"Sleep-wake disturbances and sleep disorders in patients with dementia", section on 'Sleep changes in aging and dementia'</a>.)</p><p>Nonpharmacologic treatment strategies are generally preferred. Many aspects of good sleep hygiene that are emphasized in the management of insomnia in the general population can be adapted for patients with dementia. Implementing an activity/exercise program, increasing natural light exposure during the mornings, limiting evening beverages, and eliminating evening alcohol and coffee are all useful in this patient population [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/97863.html" rel="external">"Sleep-wake disturbances and sleep disorders in patients with dementia", section on 'Management'</a>.)</p><p>In addition, certain sleep disorders occur with increased prevalence in patients with certain types of dementia. Recognition and treatment of such disorders, such as restless legs syndrome/Willis-Ekbom disease or rapid eye movement (REM) sleep behavior disorder (common among patients with Parkinson disease, dementia with Lewy bodies [DLB], and multiple system atrophy) is important and may result in improved daytime symptoms. (See  <a class="medical medical_review" href="/z/d/html/97863.html" rel="external">"Sleep-wake disturbances and sleep disorders in patients with dementia", section on 'Other disorders'</a>.)</p><p class="headingAnchor" id="H1560969780"><span class="h1">WANDERING</span><span class="headingEndMark"> — </span>Distractibility and restlessness may lead to wandering. The issue of wandering and becoming lost, with the attendant potential for physical harm or death, is one of the concerns that often leads families and caregivers to place patients with dementia in nursing homes. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5080.html" rel="external">"Management of the patient with dementia", section on 'Wandering and becoming lost'</a>.)</p><p class="headingAnchor" id="H1560969786"><span class="h1">SEXUALLY INAPPROPRIATE BEHAVIOR</span><span class="headingEndMark"> — </span>Surveys and observational studies report that a significant number (15 to 25 percent) of patients with dementia exhibit sexually inappropriate behavior [<a href="#rid147">147-151</a>]. This may be an underestimate, as caregivers may be embarrassed to report this behavior to a clinician. Examples of sexually inappropriate behavior include inappropriate explicit sex talk and sex acts (grabbing, fondling, public masturbation, exposing). Other behavioral symptoms (agitation, aggression, and/or depression) are usually present. This problem occurs in vascular dementia as well as Alzheimer disease (AD) and other neurodegenerative dementias.</p><p>A limited number of studies have investigated this problem, almost always in men, and usually in the form of small case series or case reports. Efficacy has been reported with a variety of psychotropic medications including antidepressants, antipsychotic agents, and cholinesterase inhibitors, as well as <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9774" href="/z/d/drug information/9774.html" rel="external">pindolol</a>, and <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">cimetidine</a> [<a href="#rid151">151-155</a>]. Hormonal agents (eg, <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a>, diethylstilbestrol, estrogen, <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a>) have also been used, with anecdotal reports of efficacy [<a href="#rid151">151,154-156</a>]. However, given their side effect profile, these are not considered first-line agents.</p><p>Given the absence of controlled clinical data, treatment for this problem is necessarily empiric. Behavioral interventions (redirection, distraction, avoiding stimulants) should be tried first. If this is insufficient, medication trials seem reasonable [<a href="#rid148">148,154</a>]. One systematic review concluded that the preponderance of anecdotal data provided the most support for antidepressant agents, making these the first drug of choice [<a href="#rid155">155</a>] (see <a class="local">'Antidepressant medication'</a> above). Another valid approach may be to examine the context of other behavioral symptoms that the patient may be experiencing and to try an agent that seems most appropriate for the overall symptom complex [<a href="#rid151">151</a>].</p><p class="headingAnchor" id="H25"><span class="h1">SUPPORT FOR CAREGIVERS</span><span class="headingEndMark"> — </span>Caregivers of patients with dementia can suffer significant stress, particularly as cognitive function declines or behavioral symptoms worsen [<a href="#rid157">157</a>]. Respite care and support groups are available in most areas, often through the local agency on aging. (See  <a class="medical medical_review" href="/z/d/html/5080.html" rel="external">"Management of the patient with dementia", section on 'Support for caregivers'</a>.)</p><p>Nationally, information can be obtained from the Alzheimer's Association at 1-800-272-3900, or on the internet at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.alz.org%2F&amp;token=%2BCjrhIBVW0jZK35njTvgce446Zvsbd35zfuH3%2FIfK7A%3D&amp;TOPIC_ID=5082" target="_blank">www.alz.org</a>. Information regarding frontotemporal dementia (FTD) can be found at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.theaftd.org%2F&amp;token=Pby%2FnGkMB8TdW5V6epNUr09tf%2FXjzOKUV2stcTuRs7ivALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=5082" target="_blank">www.theaftd.org</a>.</p><p class="headingAnchor" id="H548038941"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116344.html" rel="external">"Society guideline links: Cognitive impairment and dementia"</a>.)</p><p class="headingAnchor" id="H3550645"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15523.html" rel="external">"Patient education: Dementia (including Alzheimer disease) (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16421.html" rel="external">"Patient education: Caring for someone with Alzheimer disease or dementia (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/736.html" rel="external">"Patient education: Dementia (including Alzheimer disease) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – Neuropsychiatric symptoms are common in dementia  (<a class="graphic graphic_table graphicRef95072" href="/z/d/graphic/95072.html" rel="external">table 1</a>) and contribute to nursing home admission and caregiver stress. Because these symptoms may not be volunteered, clinicians should routinely ask about them. (See <a class="local">'Symptom assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment for underlying causes</strong> – When a patient with dementia develops neuropsychiatric symptoms, the first step is to identify precipitating factors and rule out and treat a medical cause or superimposed delirium  (<a class="graphic graphic_table graphicRef59893" href="/z/d/graphic/59893.html" rel="external">table 4</a>). (See <a class="local">'Evaluation for underlying cause'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpharmacologic approaches</strong> – Environmental, behavioral, and other nonpharmacologic therapies can be effective in this population and, when appropriate, are preferred over medications, which have a high rate of adverse effects. (See <a class="local">'Nonpharmacologic therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain management</strong> – Pain can aggravate behavioral disturbances in patients with dementia. Both interview and observation should be used to determine whether pain reporting represents pain-related suffering, pain perseveration, or a signal of some other type of distress. (See <a class="local">'Pain assessment'</a> above.)</p><p></p><p class="bulletIndent1">Appropriate pain management includes a stepped-care approach, starting low and titrating slowly. (See <a class="local">'Pain management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of cholinesterase inhibitors</strong> – Cholinesterase inhibitors do not produce clinically significant improvement in neuropsychiatric symptoms in patients with dementia. However, patients are often treated with these drugs because of modest improvement in cognition. (See <a class="local">'Antidementia drugs'</a> above and  <a class="medical medical_review" href="/z/d/html/5072.html" rel="external">"Cholinesterase inhibitors in the treatment of dementia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Depression</strong> – A trial of selective serotonin reuptake inhibitors (SSRIs) is suggested for the treatment of depression in Alzheimer disease (AD) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">Citalopram</a> is often used because of its possible additional benefits for other neuropsychiatric symptoms; the dose of citalopram should not exceed 20 mg daily in older adult patients. <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">Sertraline</a> is a well-studied alternative to citalopram. Tricyclics should be avoided because of side effects and drug interactions. (See <a class="local">'Antidepressant medication'</a> above and <a class="local">'Depression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe or refractory agitation</strong> – Antipsychotic agents have limited efficacy and are associated with increased mortality in patients with dementia. However, alternatives are limited when symptoms are severe, disabling, and/or threatening patient or caregiver safety despite safer interventions.</p><p></p><p class="bulletIndent1">When antipsychotic drugs are deemed necessary, we suggest low doses of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> or <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) after informing families of the mortality risk. Short-term use when possible, with regular reassessments of risks and benefits, is advised. (See <a class="local">'Antipsychotic drugs'</a> above.)</p><p></p><p class="bulletIndent1">Patients with dementia with Lewy bodies (DLB) are at especially high risk of severe side effects with neuroleptic medications. When pharmacotherapy is necessary for treatment of behavioral symptoms in such patients, only very low doses of certain atypical neuroleptics (eg, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>) should be used. (See  <a class="medical medical_review" href="/z/d/html/5087.html" rel="external">"Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies"</a>.)</p><p></p><p class="bulletIndent1">Physical restraints are rarely indicated in the care of patients with dementia and should be used only for patients who pose an imminent risk of physical harm to themselves or others. (See <a class="local">'Use of physical restraints'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Apathy</strong> – Apathy is a common and challenging symptom of dementia that can exist with and without comorbid depression. Treatment strategies include a cholinesterase inhibitor, a therapeutic trial of an antidepressant, and low-dose <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a>. (See <a class="local">'Apathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sleep disturbances</strong> – Sleep disturbances are common in patients with dementia. Nonpharmacologic strategies, including maintaining good sleep hygiene, maximizing morning natural light, and getting daily exercise, are generally preferred to pharmacotherapy. (See  <a class="medical medical_review" href="/z/d/html/97863.html" rel="external">"Sleep-wake disturbances and sleep disorders in patients with dementia"</a>.)</p><p></p><p class="headingAnchor" id="H639154218"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael Alexander, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cummings J, Ritter A, Rothenberg K. Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases. Curr Psychiatry Rep 2019; 21:79.</a></li><li><a class="nounderline abstract_t">Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46:130.</a></li><li><a class="nounderline abstract_t">Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157:708.</a></li><li><a class="nounderline abstract_t">Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA 2002; 288:1475.</a></li><li><a class="nounderline abstract_t">Sink KM, Covinsky KE, Newcomer R, Yaffe K. Ethnic differences in the prevalence and pattern of dementia-related behaviors. J Am Geriatr Soc 2004; 52:1277.</a></li><li><a class="nounderline abstract_t">Peters KR, Rockwood K, Black SE, et al. Characterizing neuropsychiatric symptoms in subjects referred to dementia clinics. Neurology 2006; 66:523.</a></li><li><a class="nounderline abstract_t">Scarmeas N, Brandt J, Blacker D, et al. Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol 2007; 64:1755.</a></li><li><a class="nounderline abstract_t">O'Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992; 5:45.</a></li><li><a class="nounderline abstract_t">Morriss RK, Rovner BW, Folstein MF, German PS. Delusions in newly admitted residents of nursing homes. Am J Psychiatry 1990; 147:299.</a></li><li><a class="nounderline abstract_t">Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol 2005; 62:1601.</a></li><li><a class="nounderline abstract_t">Gallagher-Thompson D, Brooks JO 3rd, Bliwise D, et al. The relations among caregiver stress, "sundowning" symptoms, and cognitive decline in Alzheimer's disease. J Am Geriatr Soc 1992; 40:807.</a></li><li><a class="nounderline abstract_t">Savva GM, Zaccai J, Matthews FE, et al. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry 2009; 194:212.</a></li><li><a class="nounderline abstract_t">Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA 2012; 308:2020.</a></li><li><a class="nounderline abstract_t">Ancoli-Israel S, Gehrman P, Martin JL, et al. Increased light exposure consolidates sleep and strengthens circadian rhythms in severe Alzheimer's disease patients. Behav Sleep Med 2003; 1:22.</a></li><li><a class="nounderline abstract_t">Evans LK. Sundown syndrome in institutionalized elderly. J Am Geriatr Soc 1987; 35:101.</a></li><li><a class="nounderline abstract_t">Vitiello MV, Bliwise DL, Prinz PN. Sleep in Alzheimer's disease and the sundown syndrome. Neurology 1992; 42:83.</a></li><li><a class="nounderline abstract_t">Volicer L, Harper DG, Manning BC, et al. Sundowning and circadian rhythms in Alzheimer's disease. Am J Psychiatry 2001; 158:704.</a></li><li><a class="nounderline abstract_t">Martin J, Marler M, Shochat T, Ancoli-Israel S. Circadian rhythms of agitation in institutionalized patients with Alzheimer's disease. Chronobiol Int 2000; 17:405.</a></li><li><a class="nounderline abstract_t">Chibnall JT, Tait RC. Pain assessment in cognitively impaired and unimpaired older adults: a comparison of four scales. Pain 2001; 92:173.</a></li><li><a class="nounderline abstract_t">AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc 2002; 50:S205.</a></li><li><a class="nounderline abstract_t">Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc 2003; 4:9.</a></li><li><a class="nounderline abstract_t">Sky AJ, Grossberg GT. The use of psychotropic medication in the management of problem behaviors in the patient with Alzheimer's disease. Med Clin North Am 1994; 78:811.</a></li><li><a class="nounderline abstract_t">Gitlin LN, Winter L, Dennis MP, et al. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention. J Am Geriatr Soc 2010; 58:1465.</a></li><li><a class="nounderline abstract_t">Lin FR, Yaffe K, Xia J, et al. Hearing loss and cognitive decline in older adults. JAMA Intern Med 2013; 173:293.</a></li><li><a class="nounderline abstract_t">Callahan CM, Boustani MA, Unverzagt FW, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA 2006; 295:2148.</a></li><li><a class="nounderline abstract_t">Vickrey BG, Mittman BS, Connor KI, et al. The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial. Ann Intern Med 2006; 145:713.</a></li><li><a class="nounderline abstract_t">Pieper MJ, Francke AL, van der Steen JT, et al. Effects of a Stepwise Multidisciplinary Intervention for Challenging Behavior in Advanced Dementia: A Cluster Randomized Controlled Trial. J Am Geriatr Soc 2016; 64:261.</a></li><li><a class="nounderline abstract_t">Gurwitz JH, Bonner A, Berwick DM. Reducing Excessive Use of Antipsychotic Agents in Nursing Homes. JAMA 2017; 318:118.</a></li><li><a class="nounderline abstract_t">Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet 2017; 390:2673.</a></li><li><a class="nounderline abstract_t">Ayalon L, Gum AM, Feliciano L, Areán PA. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med 2006; 166:2182.</a></li><li><a class="nounderline abstract_t">Gitlin LN, Winter L, Dennis MP, et al. A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: the COPE randomized trial. JAMA 2010; 304:983.</a></li><li><a class="nounderline abstract_t">Moniz Cook ED, Swift K, James I, et al. Functional analysis-based interventions for challenging behaviour in dementia. Cochrane Database Syst Rev 2012; :CD006929.</a></li><li><a class="nounderline abstract_t">Livingston G, Kelly L, Lewis-Holmes E, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry 2014; 205:436.</a></li><li><a class="nounderline abstract_t">Sloane PD, Hoeffer B, Mitchell CM, et al. Effect of person-centered showering and the towel bath on bathing-associated aggression, agitation, and discomfort in nursing home residents with dementia: a randomized, controlled trial. J Am Geriatr Soc 2004; 52:1795.</a></li><li><a class="nounderline abstract_t">Forrester LT, Maayan N, Orrell M, et al. Aromatherapy for dementia. Cochrane Database Syst Rev 2014; :CD003150.</a></li><li><a class="nounderline abstract_t">Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 2003; 290:2015.</a></li><li><a class="nounderline abstract_t">Clark ME, Lipe AW, Bilbrey M. Use of music to decrease aggressive behaviors in people with dementia. J Gerontol Nurs 1998; 24:10.</a></li><li><a class="nounderline abstract_t">Gerdner LA. Effects of individualized versus classical "relaxation" music on the frequency of agitation in elderly persons with Alzheimer's disease and related disorders. Int Psychogeriatr 2000; 12:49.</a></li><li><a class="nounderline abstract_t">Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 2001; 9:361.</a></li><li><a class="nounderline abstract_t">van der Steen JT, van Soest-Poortvliet MC, van der Wouden JC, et al. Music-based therapeutic interventions for people with dementia. Cochrane Database Syst Rev 2017; 5:CD003477.</a></li><li><a class="nounderline abstract_t">Viggo Hansen N, Jørgensen T, Ørtenblad L. Massage and touch for dementia. Cochrane Database Syst Rev 2006; :CD004989.</a></li><li><a class="nounderline abstract_t">Scherder E, Herr K, Pickering G, et al. Pain in dementia. Pain 2009; 145:276.</a></li><li><a class="nounderline abstract_t">Husebo BS, Ballard C, Sandvik R, et al. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ 2011; 343:d4065.</a></li><li><a class="nounderline abstract_t">Sandvik RK, Selbaek G, Seifert R, et al. Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial. Eur J Pain 2014; 18:1490.</a></li><li><a class="nounderline abstract_t">The management of chronic pain in older persons: AGS Panel on Chronic Pain in Older Persons. American Geriatrics Society. J Am Geriatr Soc 1998; 46:635.</a></li><li><a class="nounderline abstract_t">Wang J, Yu JT, Wang HF, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2015; 86:101.</a></li><li><a class="nounderline abstract_t">Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289:210.</a></li><li><a class="nounderline abstract_t">Cummings JL, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006; 67:57.</a></li><li><a class="nounderline abstract_t">Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008; 69:341.</a></li><li><a class="nounderline abstract_t">Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293:596.</a></li><li><a class="nounderline abstract_t">McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; :CD003154.</a></li><li class="breakAll">FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm (Accessed on March 28, 2012).</li><li><a class="nounderline abstract_t">Bergh S, Selbæk G, Engedal K. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. BMJ 2012; 344:e1566.</a></li><li><a class="nounderline abstract_t">Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011; :CD008191.</a></li><li><a class="nounderline abstract_t">Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159:460.</a></li><li><a class="nounderline abstract_t">Finkel SI, Mintzer JE, Dysken M, et al. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry 2004; 19:9.</a></li><li><a class="nounderline abstract_t">Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990; 157:894.</a></li><li><a class="nounderline abstract_t">Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1997; 9:591.</a></li><li><a class="nounderline abstract_t">Olafsson K, Jørgensen S, Jensen HV, et al. Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand 1992; 85:453.</a></li><li><a class="nounderline abstract_t">Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 2014; 311:682.</a></li><li><a class="nounderline abstract_t">Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007; 15:942.</a></li><li><a class="nounderline abstract_t">Gaber S, Ronzoli S, Bruno A, Biagi A. Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia. Arch Gerontol Geriatr Suppl 2001; 7:159.</a></li><li><a class="nounderline abstract_t">Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55:1271.</a></li><li><a class="nounderline abstract_t">Sultzer DL, Gray KF, Gunay I, et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997; 5:60.</a></li><li><a class="nounderline abstract_t">Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155:54.</a></li><li><a class="nounderline abstract_t">Olin JT, Fox LS, Pawluczyk S, et al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001; 9:400.</a></li><li><a class="nounderline abstract_t">Lindenmayer JP, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry 2000; 61:123.</a></li><li><a class="nounderline abstract_t">Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001; 9:58.</a></li><li><a class="nounderline abstract_t">Herrmann N, Lanctôt K, Myszak M. Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. J Clin Psychopharmacol 2000; 20:90.</a></li><li><a class="nounderline abstract_t">Riemersma-van der Lek RF, Swaab DF, Twisk J, et al. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA 2008; 299:2642.</a></li><li><a class="nounderline abstract_t">Jansen SL, Forbes DA, Duncan V, Morgan DG. Melatonin for cognitive impairment. Cochrane Database Syst Rev 2006; :CD003802.</a></li><li><a class="nounderline abstract_t">Gehrman PR, Connor DJ, Martin JL, et al. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am J Geriatr Psychiatry 2009; 17:166.</a></li><li><a class="nounderline abstract_t">Dowling GA, Burr RL, Van Someren EJ, et al. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. J Am Geriatr Soc 2008; 56:239.</a></li><li><a class="nounderline abstract_t">Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003; 26:893.</a></li><li><a class="nounderline abstract_t">McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer's disease. Cochrane Database Syst Rev 2014; :CD009178.</a></li><li><a class="nounderline abstract_t">de Jonghe A, Korevaar JC, van Munster BC, de Rooij SE. Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. Int J Geriatr Psychiatry 2010; 25:1201.</a></li><li><a class="nounderline abstract_t">Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26:494.</a></li><li><a class="nounderline abstract_t">Borson S, Raskind MA. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology 1997; 48:S17.</a></li><li><a class="nounderline abstract_t">Corbett A, Burns A, Ballard C. Don't use antipsychotics routinely to treat agitation and aggression in people with dementia. BMJ 2014; 349:g6420.</a></li><li><a class="nounderline abstract_t">Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. Am J Psychiatry 2016; 173:543.</a></li><li><a class="nounderline abstract_t">Antipsychotic drugs for dementia: a balancing act. Lancet Neurol 2009; 8:125.</a></li><li><a class="nounderline abstract_t">Declercq T, Petrovic M, Azermai M, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev 2013; :CD007726.</a></li><li><a class="nounderline abstract_t">Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med 2012; 367:1497.</a></li><li><a class="nounderline abstract_t">Tariot PN, Cummings JL, Soto-Martin ME, et al. Trial of Pimavanserin in Dementia-Related Psychosis. N Engl J Med 2021; 385:309.</a></li><li><a class="nounderline abstract_t">Ballard C, Orrell M, YongZhong S, et al. Impact of Antipsychotic Review and Nonpharmacological Intervention on Antipsychotic Use, Neuropsychiatric Symptoms, and Mortality in People With Dementia Living in Nursing Homes: A Factorial Cluster-Randomized Controlled Trial by the Well-Being and Health for People With Dementia (WHELD) Program. Am J Psychiatry 2016; 173:252.</a></li><li><a class="nounderline abstract_t">Patel AN, Lee S, Andrews HF, et al. Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations. Am J Psychiatry 2017; 174:362.</a></li><li><a class="nounderline abstract_t">Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002; :CD002852.</a></li><li><a class="nounderline abstract_t">Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329:75.</a></li><li><a class="nounderline abstract_t">Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14:191.</a></li><li><a class="nounderline abstract_t">Ballard C, Banister C, Khan Z, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol 2018; 17:213.</a></li><li><a class="nounderline abstract_t">Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005; 330:874.</a></li><li><a class="nounderline abstract_t">Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355:1525.</a></li><li><a class="nounderline abstract_t">Devanand DP, Sackeim HA, Brown RP, Mayeux R. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 1989; 46:854.</a></li><li><a class="nounderline abstract_t">Dev VJ, Rosenberg T, Krupp P. Agranulocytosis and clozapine. BMJ 1994; 309:54.</a></li><li><a class="nounderline abstract_t">Atypical antipsychotics in the elderly. Med Lett Drugs Ther 2005; 47:61.</a></li><li><a class="nounderline abstract_t">Kuehn BM. FDA warns antipsychotic drugs may be risky for elderly. JAMA 2005; 293:2462.</a></li><li><a class="nounderline abstract_t">Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934.</a></li><li><a class="nounderline abstract_t">Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8:151.</a></li><li><a class="nounderline abstract_t">Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353:2335.</a></li><li><a class="nounderline abstract_t">Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007; 176:627.</a></li><li><a class="nounderline abstract_t">Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012; 344:e977.</a></li><li><a class="nounderline abstract_t">Gerhard T, Huybrechts K, Olfson M, et al. Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry 2014; 205:44.</a></li><li><a class="nounderline abstract_t">Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2012; 169:71.</a></li><li><a class="nounderline abstract_t">Rossom RC, Rector TS, Lederle FA, Dysken MW. Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc 2010; 58:1027.</a></li><li><a class="nounderline abstract_t">Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 2015; 72:438.</a></li><li><a class="nounderline abstract_t">Weintraub D, Chiang C, Kim HM, et al. Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. JAMA Neurol 2016; 73:535.</a></li><li><a class="nounderline abstract_t">Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008; 168:1090.</a></li><li><a class="nounderline abstract_t">Howard R, Costafreda SG, Karcher K, et al. Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients. Br J Psychiatry 2016; 209:378.</a></li><li><a class="nounderline abstract_t">Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64:134.</a></li><li><a class="nounderline abstract_t">Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 167:1269.</a></li><li><a class="nounderline abstract_t">Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170:1395.</a></li><li><a class="nounderline abstract_t">Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161:1113.</a></li><li><a class="nounderline abstract_t">Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330:445.</a></li><li><a class="nounderline abstract_t">Barnett MJ, Wehring H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol 2007; 27:595.</a></li><li><a class="nounderline abstract_t">Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010; 68:693.</a></li><li><a class="nounderline abstract_t">Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004; 63:1364.</a></li><li><a class="nounderline abstract_t">Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA 2015; 314:1242.</a></li><li><a class="nounderline abstract_t">Ballard C, Sharp S, Corbett A. Dextromethorphan and Quinidine for Treating Agitation in Patients With Alzheimer Disease Dementia. JAMA 2015; 314:1233.</a></li><li class="breakAll">American Psychiatric Association Practice Guideline: Treatment of patients with Alzheimer's disease and other dementias, Second edition. http://psychiatryonline.org/content.aspx?bookid=28&amp;sectionid=1679489.</li><li><a class="nounderline abstract_t">Kröpelin TF, Neyens JC, Halfens RJ, et al. Fall determinants in older long-term care residents with dementia: a systematic review. Int Psychogeriatr 2013; 25:549.</a></li><li><a class="nounderline abstract_t">Pellfolk TJ, Gustafson Y, Bucht G, Karlsson S. Effects of a restraint minimization program on staff knowledge, attitudes, and practice: a cluster randomized trial. J Am Geriatr Soc 2010; 58:62.</a></li><li><a class="nounderline abstract_t">Evans LK, Strumpf NE, Allen-Taylor SL, et al. A clinical trial to reduce restraints in nursing homes. J Am Geriatr Soc 1997; 45:675.</a></li><li><a class="nounderline abstract_t">Testad I, Aasland AM, Aarsland D. The effect of staff training on the use of restraint in dementia: a single-blind randomised controlled trial. Int J Geriatr Psychiatry 2005; 20:587.</a></li><li><a class="nounderline abstract_t">Kuske B, Luck T, Hanns S, et al. Training in dementia care: a cluster-randomized controlled trial of a training program for nursing home staff in Germany. Int Psychogeriatr 2009; 21:295.</a></li><li><a class="nounderline abstract_t">Jones BN, Reifler BV. Depression coexisting with dementia. Evaluation and treatment. Med Clin North Am 1994; 78:823.</a></li><li><a class="nounderline abstract_t">Dal Forno G, Palermo MT, Donohue JE, et al. Depressive symptoms, sex, and risk for Alzheimer's disease. Ann Neurol 2005; 57:381.</a></li><li><a class="nounderline abstract_t">Olin JT, Schneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry 2002; 10:125.</a></li><li><a class="nounderline abstract_t">Bains J, Birks J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev 2002; :CD003944.</a></li><li><a class="nounderline abstract_t">Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician. Dement Geriatr Cogn Disord 2004; 17:55.</a></li><li><a class="nounderline abstract_t">Kiosses DN, Ravdin LD, Gross JJ, et al. Problem adaptation therapy for older adults with major depression and cognitive impairment: a randomized clinical trial. JAMA Psychiatry 2015; 72:22.</a></li><li><a class="nounderline abstract_t">Orgeta V, Qazi A, Spector AE, Orrell M. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev 2014; :CD009125.</a></li><li><a class="nounderline abstract_t">Gottfries CG, Karlsson I, Nyth AL. Treatment of depression in elderly patients with and without dementia disorders. Int Clin Psychopharmacol 1992; 6 Suppl 5:55.</a></li><li><a class="nounderline abstract_t">Rosenberg PB, Drye LT, Martin BK, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 2010; 18:136.</a></li><li><a class="nounderline abstract_t">Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry 2010; 18:332.</a></li><li><a class="nounderline abstract_t">Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011; 378:403.</a></li><li><a class="nounderline abstract_t">Sepehry AA, Lee PE, Hsiung GY, et al. Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. Drugs Aging 2012; 29:793.</a></li><li><a class="nounderline abstract_t">Taragano FE, Lyketsos CG, Mangone CA, et al. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997; 38:246.</a></li><li><a class="nounderline abstract_t">Clarke DE, Ko JY, Lyketsos C, et al. Apathy and cognitive and functional decline in community-dwelling older adults: results from the Baltimore ECA longitudinal study. Int Psychogeriatr 2010; 22:819.</a></li><li><a class="nounderline abstract_t">Onyike CU, Sheppard JM, Tschanz JT, et al. Epidemiology of apathy in older adults: the Cache County Study. Am J Geriatr Psychiatry 2007; 15:365.</a></li><li><a class="nounderline abstract_t">Okura T, Plassman BL, Steffens DC, et al. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: The aging, demographics, and memory study. J Am Geriatr Soc 2010; 58:330.</a></li><li><a class="nounderline abstract_t">Lavretsky H, Reinlieb M, St Cyr N, et al. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015; 172:561.</a></li><li><a class="nounderline abstract_t">Padala PR, Burke WJ, Shostrom VK, et al. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry 2010; 18:371.</a></li><li><a class="nounderline abstract_t">Padala PR, Padala KP, Lensing SY, et al. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. Am J Psychiatry 2018; 175:159.</a></li><li><a class="nounderline abstract_t">Herrmann N, Rothenburg LS, Black SE, et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol 2008; 28:296.</a></li><li><a class="nounderline abstract_t">Rosenberg PB, Lanctôt KL, Drye LT, et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry 2013; 74:810.</a></li><li><a class="nounderline abstract_t">Deschenes CL, McCurry SM. Current treatments for sleep disturbances in individuals with dementia. Curr Psychiatry Rep 2009; 11:20.</a></li><li><a class="nounderline abstract_t">Phillips VL, Diwan S, Egner A. Development of a tool for assessment and care planning for dementia-related problem behaviors in home and community-based services programs: the Problem Behavior Inventory. Home Health Care Serv Q 2002; 21:29.</a></li><li><a class="nounderline abstract_t">Alagiakrishnan K, Lim D, Brahim A, et al. Sexually inappropriate behaviour in demented elderly people. Postgrad Med J 2005; 81:463.</a></li><li><a class="nounderline abstract_t">Tsai SJ, Hwang JP, Yang CH, et al. Inappropriate sexual behaviors in dementia: a preliminary report. Alzheimer Dis Assoc Disord 1999; 13:60.</a></li><li><a class="nounderline abstract_t">Zeiss AM, Davies HD, Tinklenberg JR. An observational study of sexual behavior in demented male patients. J Gerontol A Biol Sci Med Sci 1996; 51:M325.</a></li><li><a class="nounderline abstract_t">Ozkan B, Wilkins K, Muralee S, Tampi RR. Pharmacotherapy for inappropriate sexual behaviors in dementia: a systematic review of literature. Am J Alzheimers Dis Other Demen 2008; 23:344.</a></li><li><a class="nounderline abstract_t">Prakash R, Pathak A, Munda S, Bagati D. Quetiapine effective in treatment of inappropriate sexual behavior of lewy body disease with predominant frontal lobe signs. Am J Alzheimers Dis Other Demen 2009; 24:136.</a></li><li><a class="nounderline abstract_t">Anneser JM, Jox RJ, Borasio GD. Inappropriate sexual behaviour in a case of ALS and FTD: successful treatment with sertraline. Amyotroph Lateral Scler 2007; 8:189.</a></li><li><a class="nounderline abstract_t">Black B, Muralee S, Tampi RR. Inappropriate sexual behaviors in dementia. J Geriatr Psychiatry Neurol 2005; 18:155.</a></li><li><a class="nounderline abstract_t">Guay DR. Inappropriate sexual behaviors in cognitively impaired older individuals. Am J Geriatr Pharmacother 2008; 6:269.</a></li><li><a class="nounderline abstract_t">Light SA, Holroyd S. The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia. J Psychiatry Neurosci 2006; 31:132.</a></li><li><a class="nounderline abstract_t">Aarsland D, Brønnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78:36.</a></li></ol></div><div id="topicVersionRevision">Topic 5082 Version 61.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31392434" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8559361" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The spectrum of behavioral changes in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10784462" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12243634" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15271114" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ethnic differences in the prevalence and pattern of dementia-related behaviors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16505306" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Characterizing neuropsychiatric symptoms in subjects referred to dementia clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071039" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Disruptive behavior as a predictor in Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571074" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incontinence and troublesome behaviors predict institutionalization in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2309945" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Delusions in newly admitted residents of nursing homes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16216946" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Delusions and hallucinations are associated with worse outcome in Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1634724" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The relations among caregiver stress, "sundowning" symptoms, and cognitive decline in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19252147" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23168825" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nonpharmacologic management of behavioral symptoms in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15600135" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Increased light exposure consolidates sleep and strengthens circadian rhythms in severe Alzheimer's disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3805551" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Sundown syndrome in institutionalized elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1630644" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sleep in Alzheimer's disease and the sundown syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11329390" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sundowning and circadian rhythms in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10841213" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Circadian rhythms of agitation in institutionalized patients with Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11323138" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pain assessment in cognitively impaired and unimpaired older adults: a comparison of four scales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12067390" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The management of persistent pain in older persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12807591" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7912756" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The use of psychotropic medication in the management of problem behaviors in the patient with Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20662955" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23337978" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hearing loss and cognitive decline in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16684985" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116916" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26804064" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effects of a Stepwise Multidisciplinary Intervention for Challenging Behavior in Advanced Dementia: A Cluster Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28617907" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Reducing Excessive Use of Antipsychotic Agents in Nursing Homes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28735855" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Dementia prevention, intervention, and care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17101935" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20810376" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: the COPE randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336826" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Functional analysis-based interventions for challenging behaviour in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25452601" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15507054" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of person-centered showering and the towel bath on bathing-associated aggression, agitation, and discomfort in nursing home residents with dementia: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24569873" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Aromatherapy for dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14559955" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9801526" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Use of music to decrease aggressive behaviors in people with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10798453" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effects of individualized versus classical "relaxation" music on the frequency of agitation in elderly persons with Alzheimer's disease and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739063" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28462986" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Music-based therapeutic interventions for people with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17054228" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Massage and touch for dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19409705" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pain in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21765198" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24819710" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9588381" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The management of chronic pain in older persons: AGS Panel on Chronic Pain in Older Persons. American Geriatrics Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24876182" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517232" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16832078" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18294023" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15687315" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625572" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Memantine for dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625572" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Memantine for dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22408266" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21328305" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Antidepressants for agitation and psychosis in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870012" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14716694" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1705151" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9447502" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1642129" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24549548" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17846102" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11431060" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11087767" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9169246" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9433339" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739066" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10732659" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Use of sodium valproate in violent and aggressive behaviors: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11156753" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Placebo-controlled study of divalproex sodium for agitation in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10653214" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effectiveness of gabapentin for the treatment of behavioral disorders in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18544724" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16437462" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Melatonin for cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155748" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18070004" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655926" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24659320" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pharmacotherapies for sleep disturbances in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21086534" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11927174" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153156" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25368388" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Don't use antipsychotics routinely to treat agitation and aggression in people with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27133416" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19161899" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Antipsychotic drugs for dementia: a balancing act.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543555" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23075176" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Relapse risk after discontinuation of risperidone in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34289275" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Trial of Pimavanserin in Dementia-Related Psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26585409" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Impact of Antipsychotic Review and Nonpharmacological Intervention on Antipsychotic Use, Neuropsychiatric Symptoms, and Mortality in People With Dementia Living in Nursing Homes: A Factorial Cluster-Randomized Controlled Trial by the Well-Being and Health for People With Dementia (WHELD) Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27855483" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12076456" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Haloperidol for agitation in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15194601" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16505124" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29452684" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15722369" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17035647" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2667504" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8044077" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Agranulocytosis and clozapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16052161" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Atypical antipsychotics in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15914734" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : FDA warns antipsychotic drugs may be risky for elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16234500" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19138567" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16319382" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Risk of death in elderly users of conventional vs. atypical antipsychotic medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17325327" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22362541" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23929443" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Comparative mortality risks of antipsychotic medications in community-dwelling older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22193526" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Risk of mortality among individual antipsychotics in patients with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20487081" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25786075" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26999262" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18504337" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Antipsychotic therapy and short-term serious events in older adults with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27388570" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12633121" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12451085" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15111472" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15169702" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Atypical antipsychotics and risk of cerebrovascular accidents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668211" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18004126" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20839238" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15505150" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26393847" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26393843" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Dextromethorphan and Quinidine for Treating Agitation in Patients With Alzheimer Disease Dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26393843" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Dextromethorphan and Quinidine for Treating Agitation in Patients With Alzheimer Disease Dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23253253" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Fall determinants in older long-term care residents with dementia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20122041" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Effects of a restraint minimization program on staff knowledge, attitudes, and practice: a cluster randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9180659" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : A clinical trial to reduce restraints in nursing homes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15920716" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : The effect of staff training on the use of restraint in dementia: a single-blind randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19193252" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Training in dementia care: a cluster-randomized controlled trial of a training program for nursing home staff in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8022231" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Depression coexisting with dementia. Evaluation and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15732103" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Depressive symptoms, sex, and risk for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11925273" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Provisional diagnostic criteria for depression of Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12519625" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Antidepressants for treating depression in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14564126" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25372657" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Problem adaptation therapy for older adults with major depression and cognitive impairment: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24449085" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Psychological treatments for depression and anxiety in dementia and mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1431023" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Treatment of depression in elderly patients with and without dementia disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20087081" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Sertraline for the treatment of depression in Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20220589" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21764118" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23079957" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9136253" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20478091" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Apathy and cognitive and functional decline in community-dwelling older adults: results from the Baltimore ECA longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17463187" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Epidemiology of apathy in older adults: the Cache County Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20374406" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25677354" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20220576" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Methylphenidate for apathy and functional status in dementia of the Alzheimer type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945120" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18480686" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24021498" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19187704" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Current treatments for sleep disturbances in individuals with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196933" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Development of a tool for assessment and care planning for dementia-related problem behaviors in home and community-based services programs: the Problem Behavior Inventory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15998824" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Sexually inappropriate behaviour in demented elderly people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10192644" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Inappropriate sexual behaviors in dementia: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8914506" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : An observational study of sexual behavior in demented male patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18509106" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Pharmacotherapy for inappropriate sexual behaviors in dementia: a systematic review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19129547" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Quetiapine effective in treatment of inappropriate sexual behavior of lewy body disease with predominant frontal lobe signs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538783" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Inappropriate sexual behaviour in a case of ALS and FTD: successful treatment with sertraline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100105" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Inappropriate sexual behaviors in dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19161930" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Inappropriate sexual behaviors in cognitively impaired older individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575429" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16820421" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
